Repligen (NASDAQ:RGEN) Downgraded to Sell Rating by StockNews.com

StockNews.com lowered shares of Repligen (NASDAQ:RGEN) from a hold rating to a sell rating in a research note issued to investors on Friday morning.

A number of other equities analysts have also weighed in on RGEN. Canaccord Genuity Group upped their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $180.00 target price on shares of Repligen in a research note on Friday. Royal Bank of Canada raised their price target on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $183.36.

Repligen Trading Down 2.3 %

NASDAQ RGEN opened at $158.99 on Friday. Repligen has a one year low of $113.50 and a one year high of $203.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a market cap of $8.91 billion, a P/E ratio of -429.69, a P/E/G ratio of 4.23 and a beta of 0.99. The stock’s 50-day moving average is $155.22 and its 200-day moving average is $148.79.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Sell-side analysts anticipate that Repligen will post 1.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RGEN. CWM LLC increased its position in Repligen by 36.3% during the third quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock worth $64,000 after buying an additional 114 shares during the last quarter. Creative Planning boosted its stake in shares of Repligen by 32.6% during the 3rd quarter. Creative Planning now owns 5,123 shares of the biotechnology company’s stock worth $762,000 after acquiring an additional 1,259 shares during the period. Blue Trust Inc. increased its holdings in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares during the last quarter. Raymond James & Associates raised its stake in Repligen by 49.3% in the 3rd quarter. Raymond James & Associates now owns 82,277 shares of the biotechnology company’s stock valued at $12,244,000 after acquiring an additional 27,158 shares during the period. Finally, Greenleaf Trust acquired a new stake in Repligen during the 3rd quarter valued at $226,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.